Esther Meijer Selected Research

Vasopressin Receptors (Arginine Vasopressin Receptor)

1/2022	Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.
3/2021	Acid-Base Homeostasis During Vasopressin V2 Receptor Antagonist Treatment in Autosomal Dominant Polycystic Kidney Disease Patients.
1/2020	Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability.
1/2019	Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
12/2018	Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
1/2018	Case report: a thiazide diuretic to treat polyuria induced by tolvaptan.
6/2017	Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients.
1/2016	Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.
10/2015	Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
6/2015	Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Esther Meijer Research Topics

Disease

43	Autosomal Dominant Polycystic Kidney (ADPKD) 07/2022 - 06/2010
12	Disease Progression 01/2022 - 06/2012
8	Cysts 07/2022 - 05/2011
6	Chronic Renal Insufficiency 06/2019 - 12/2013
3	Infections 07/2022 - 01/2017
3	Polyuria 01/2022 - 06/2017
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2021 - 08/2009
2	Intractable Pain 07/2022 - 05/2022
2	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 06/2019
2	Polycystic Kidney Diseases (Polycystic Kidney Disease) 06/2021 - 05/2011
2	Polycystic liver disease 01/2019 - 03/2014
2	Albuminuria 11/2016 - 11/2010
2	Proteinuria 01/2016 - 11/2011
1	Pain (Aches) 05/2022
1	Chronic Pain 05/2022
1	Hematuria 01/2022
1	Nephritis 01/2022
1	Ciliopathies 01/2022
1	Gallstones (Gallstone) 06/2021
1	Nocturia 06/2020
1	Kidney Diseases (Kidney Disease) 01/2019
1	Hypertension (High Blood Pressure) 01/2018
1	Nephrogenic Diabetes Insipidus 01/2018
1	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2016
1	Neoplasms (Cancer) 12/2008

Drug/Important Bio-Agent (IBA)

11	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2022 - 05/2011
11	Tolvaptan FDA Link 01/2022 - 05/2011
10	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2010
9	Vasopressins (Vasopressin)IBA 01/2021 - 08/2009
7	lanreotide (Somatuline)FDA Link 06/2021 - 03/2014
7	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 06/2021 - 03/2014
7	CreatinineIBA 06/2019 - 05/2011
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2011
4	AlbuminsIBA 01/2019 - 06/2010
3	Pharmaceutical PreparationsIBA 01/2022 - 10/2015
2	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2022 - 01/2018
2	AcidsIBA 06/2021 - 03/2021
2	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 01/2019
2	SaltsIBA 01/2021 - 10/2020
2	Urea (Carbamide)FDA LinkGeneric 01/2021 - 09/2014
2	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 01/2021 - 01/2018
2	Immunoglobulin G (IgG)IBA 01/2019 - 11/2011
2	Lipocalin-2IBA 01/2019 - 01/2016
2	TEMPOIBA 11/2016 - 05/2011
2	LigandsIBA 01/2016 - 10/2015
2	ErbB Receptors (EGF Receptor)IBA 01/2016 - 10/2015
2	Edetic Acid (EDTA)FDA Link 12/2014 - 09/2014
2	Arginine Vasopressin (Argipressin)IBA 09/2014 - 03/2013
1	Opioid Analgesics (Opioids)IBA 05/2022
1	Analgesics (Analgesic Drugs)IBA 05/2022
1	Metformin (Glucophage)FDA LinkGeneric 01/2022
1	antiglomerular basement membrane antibodyIBA 01/2022
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2022
1	DiureticsIBA 01/2021
1	ThiazidesIBA 01/2021
1	Temazepam (Nocturne)FDA LinkGeneric 06/2020
1	Adenosine (Adenocard)FDA LinkGeneric 01/2020
1	Insulin-Like Growth Factor Binding ProteinsIBA 06/2019
1	ImmunosorbentsIBA 06/2019
1	EnzymesIBA 06/2019
1	Tissue Inhibitor of Metalloproteinase-2IBA 06/2019
1	Fatty Acid-Binding ProteinsIBA 01/2019
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2019
1	Adenosine Monophosphate (AMP)IBA 12/2018
1	Iothalamic Acid (Iotalamic Acid)FDA Link 03/2018
1	Neutralizing AntibodiesIBA 01/2016
1	Metalloproteases (Metalloproteinases)IBA 01/2016
1	Monoclonal AntibodiesIBA 01/2016
1	alpha-1-microglobulinIBA 01/2016
1	DisintegrinsIBA 01/2016
1	Tyrosine Kinase InhibitorsIBA 01/2016
1	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 10/2015
1	Epidermal Growth Factor (EGF)IBA 10/2015
1	EGF Family of ProteinsIBA 10/2015
1	Heparin (Liquaemin)FDA LinkGeneric 10/2015
1	Indicators and Reagents (Reagents)IBA 12/2014
1	Inulin FDA Link 11/2012
1	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 06/2012
1	Antidiuretic Hormone Receptor AntagonistsIBA 02/2011
1	Fatty Acid Binding Protein 3IBA 11/2010
1	Mechanistic Target of Rapamycin Complex 2IBA 12/2008
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2008

Therapy/Procedure

6	Therapeutics 05/2022 - 10/2015
3	Renal Replacement Therapy (Therapies, Renal Replacement) 11/2018 - 09/2014
2	Nephrectomy 07/2022 - 05/2022
2	Aftercare (After-Treatment) 05/2022 - 10/2015
1	Kidney Transplantation 07/2022
1	Nerve Block (Nerve Blocks) 05/2022
1	Sodium-Restricted Diet (Diet, Sodium Restricted) 01/2019